JPRN-UMIN000001905Not yet recruiting未知
se of micafungin as antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. - Use of micafungin as antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Enrollment
- 65
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 16years-old to 65years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients are free of fungal infection at the time of enrollment. Patients have a history of a serious allergy to the study drug. Patients have a serious liver dysfunction. Patients have received micafungin within 7 days before the time of enrollment.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Antifungal prophylaxis with Micafungin after cord blood allogeneic stem cell transplantation.EUCTR2013-000103-16-FRCHU de Nantes
Completed
Phase 1
Alternate Day Micafungin: A PK Study in Pediatric PatientsFungal InfectionNCT00842504Children's Hospital Medical Center, Cincinnati15
Completed
Phase 2
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute LeukemiaAcute LeukemiaNCT02440178Seoul National University Hospital66
Completed
Not Applicable
sefulness of micafungin in the empiric therapy of invasive fungal infections in surgery and intensive-care medicinePatients undergoing gastroenterological surgeryJPRN-UMIN000011388Department of infectious disease, Hiroshima University Hospital65
Active, not recruiting
Phase 1
Exposure to micafungin given twice/week compared to once/day.prophylaxis for patients at high risk for invasive fungal diseasesMedDRA version: 17.0Level: PTClassification code 10017533Term: Fungal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002848-93-BERadboud University Medical Centre20